DK2723336T3 - Sammensætninger til behandling af fragilt X-syndrom - Google Patents

Sammensætninger til behandling af fragilt X-syndrom Download PDF

Info

Publication number
DK2723336T3
DK2723336T3 DK12735048.6T DK12735048T DK2723336T3 DK 2723336 T3 DK2723336 T3 DK 2723336T3 DK 12735048 T DK12735048 T DK 12735048T DK 2723336 T3 DK2723336 T3 DK 2723336T3
Authority
DK
Denmark
Prior art keywords
fragile
syndrome
compositions
treatment
Prior art date
Application number
DK12735048.6T
Other languages
English (en)
Inventor
Sylvain Briault
Olivier Perche
Original Assignee
Centre Nat Rech Scient
Centre Hospitalier Regional Dorleans
Univ Orleans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Centre Hospitalier Regional Dorleans, Univ Orleans filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK2723336T3 publication Critical patent/DK2723336T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12735048.6T 2011-06-27 2012-06-19 Sammensætninger til behandling af fragilt X-syndrom DK2723336T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171532A EP2540295A1 (en) 2011-06-27 2011-06-27 Compositions for the treatment of Fragile X syndrome
PCT/IB2012/053089 WO2013001412A1 (en) 2011-06-27 2012-06-19 Compositions for the treatment of fragile x syndrome

Publications (1)

Publication Number Publication Date
DK2723336T3 true DK2723336T3 (da) 2020-06-29

Family

ID=44840530

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12735048.6T DK2723336T3 (da) 2011-06-27 2012-06-19 Sammensætninger til behandling af fragilt X-syndrom

Country Status (8)

Country Link
US (1) US10435366B2 (da)
EP (2) EP2540295A1 (da)
JP (1) JP6012726B2 (da)
DK (1) DK2723336T3 (da)
ES (1) ES2797395T3 (da)
PL (1) PL2723336T3 (da)
PT (1) PT2723336T (da)
WO (1) WO2013001412A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
JP6585030B2 (ja) * 2013-03-15 2019-10-02 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 自閉症スペクトラム障害におけるgaba−bアゴニスト薬物活性の脳磁図バイオマーカー
US20180116983A1 (en) 2015-02-13 2018-05-03 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation
MX2019009985A (es) 2017-02-24 2019-10-09 Ovid Therapeutics Inc Metodos para tratar trastornos convulsivos.
EP3727587A4 (en) * 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
US20020045566A1 (en) 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
US6855829B2 (en) * 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
CA2438805A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
FR2857452B1 (fr) * 2003-07-11 2005-09-30 Univ Rabelais Francois Test de depistage de l'autisme, methode de selection de patients repondant audit test et utilisation des medicaments activateurs de canaux bkca pour le traitement de ladite maladie
DE102004053673A1 (de) * 2004-11-03 2006-05-04 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massendurchflusses eines Mediums
WO2008060448A2 (en) 2006-11-10 2008-05-22 Massachusetts Institute Of Technology Small molecule pak inhibitors
EP2175886A1 (en) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome

Also Published As

Publication number Publication date
US10435366B2 (en) 2019-10-08
PT2723336T (pt) 2020-07-14
EP2723336A1 (en) 2014-04-30
JP6012726B2 (ja) 2016-10-25
EP2723336B1 (en) 2020-04-08
JP2014518255A (ja) 2014-07-28
PL2723336T3 (pl) 2020-10-19
WO2013001412A1 (en) 2013-01-03
ES2797395T3 (es) 2020-12-02
US20140221450A1 (en) 2014-08-07
EP2540295A1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK3225604T3 (da) Fremgangsmåde til fremstilling af flerlagsruder
CO6970594A2 (es) Composiciones hemostáticas
DK2791160T3 (da) Modificerede mrna-sammensætninger
CR20140147A (es) Inhibidores de aplicación viral
BR112013022112A2 (pt) composição
DK3590928T3 (da) Pyrimidinderivater til behandling af virusinfektioner
BR112013017183A2 (pt) composições de bepostatina
BR112013022102A2 (pt) composição
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
BR112014000284A2 (pt) composição fotoprotetora
DK2686017T3 (da) Oftalmisk sammensætning
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
BR112014004395A2 (pt) composição
BR112013019150A2 (pt) engenharia do âmbito da imunoglobulina
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK3513803T3 (da) Hæmostatiske sammensætninger
CO6930368A2 (es) Composiciones de yodo-povidona estable
DK2595948T3 (da) Fremgangsmåde til fremstilling af ingenol-3-angelat
DK3299356T3 (da) Fremgangsmåde til fremstilling af pleuromutiliner
BR112013033808A2 (pt) composição
DK3444238T3 (da) Fremgangsmåde til fremstilling af difluormethylenforbindelser
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
DK3524260T3 (da) Farmaceutiske sammensætninger til behandling af manglende appetit